Cyllene Therapeutics secured a $37 million Series C to advance EG110A for late-stage development in severe neurogenic bladder. The financing is intended to move the lead candidate closer to potential regulatory submissions for a patient population characterized by limited options and ongoing unmet need. EG110A adds to the growing gene therapy and regenerative-medicine push toward in vivo delivery platforms, where clinical progress hinges on consistent expression, durability of effect, and safety. The round also signals continued investor appetite for late-stage advancement in urology-adjacent indications, where development timelines and endpoints can be more straightforward than in some CNS or oncology settings.